|
1
|
Dimaras H, Corson TW, Cobrinik D, White A,
Zhao J, Munier FL, Abramson DH, Shields CL, Chantada GL, Njuguna F
and Gallie BL: Retinoblastoma. Nat Rev Dis Primers. 1:150212015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Broaddus E, Topham A and Singh AD:
Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol.
93:21–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
MacCarthy A, Draper GJ, Steliarova-Foucher
E and Kingston JE: Retinoblastoma incidence and survival in
European children (1978–1997). Report from the Automated Childhood
Cancer Information System project. Eur J Cancer. 42:2092–2102.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Benavente CA and Dyer MA: Genetics and
epigenetics of human retinoblastoma. Annu Rev Pathol. 10:547–562.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shields CL and Shields JA: Retinoblastoma
management: Advances in enucleation, intravenous chemoreduction,
and intra-arterial chemotherapy. Curr Opin Ophthalmol. 21:203–212.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dimaras H, Dimba EA and Gallie BL:
Challenging the global retinoblastoma survival disparity through a
collaborative research effort. Br J Ophthalmol. 94:1415–1416. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu X, Zeng Y, Wu S, Zhong J, Wang Y and Xu
J: MiR-204, down-regulated in retinoblastoma, regulates
proliferation and invasion of human retinoblastoma cells by
targeting CyclinD2 and MMP-9. FEBS Lett. 589:645–650. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cai Y, Yu X, Hu S and Yu J: A brief review
on the mechanisms of miRNA regulation. Genomics Proteomics
Bioinformatics. 7:147–154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pratap P, Raza ST, Abbas S and Mahdi F:
MicroRNA-associated carcinogenesis in lung carcinoma. J Cancer Res
Ther. 14:249–254. 2018.PubMed/NCBI
|
|
11
|
Vannini I, Fanini F and Fabbri M: Emerging
roles of microRNAs in cancer. Curr Opin Genet Dev. 48:128–133.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lou W, Liu J, Gao Y, Zhong G, Chen D, Shen
J, Bao C, Xu L, Pan J, Cheng J, et al: MicroRNAs in cancer
metastasis and angiogenesis. Oncotarget. 8:115787–115802. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu S, Zhang X, Hu C, Wang Y and Xu C:
miR-29a inhibits human retinoblastoma progression by targeting
STAT3. Oncol Rep. 39:739–746. 2018.PubMed/NCBI
|
|
14
|
Wang Z, Yao YJ, Zheng F, Guan Z, Zhang L,
Dong N and Qin WJ: Mir-138-5p acts as a tumor suppressor by
targeting pyruvate dehydrogenase kinase 1 in human retinoblastoma.
Eur Rev Med Pharmacol Sci. 21:5624–5629. 2017.PubMed/NCBI
|
|
15
|
Yang L, Wei N, Wang L, Wang X and Liu QH:
miR-498 promotes cell proliferation and inhibits cell apoptosis in
retinoblastoma by directly targeting CCPG1. Childs Nerv Syst.
34:417–422. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang M, Li Q, Pan Y, Wang H, Liu G and
Yin H: MicroRNA-655 attenuates the malignant biological behaviours
of retinoblastoma cells by directly targeting PAX6 and suppressing
the ERK and p38 MAPK signalling pathways. Oncol Rep. 39:2040–2050.
2018.PubMed/NCBI
|
|
17
|
Singh U, Malik MA, Goswami S, Shukla S and
Kaur J: Epigenetic regulation of human retinoblastoma. Tumour Biol.
37:14427–14441. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Golabchi K, Soleimani-Jelodar R, Aghadoost
N, Momeni F, Moridikia A, Nahand JS, Masoudifar A, Razmjoo H and
Mirzaei H: MicroRNAs in retinoblastoma: Potential diagnostic and
therapeutic biomarkers. J Cell Physiol. 233:3016–3023. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu X, Ge S, Jia R, Zhou Y, Song X, Zhang H
and Fan X: Hypoxia-induced miR-181b enhances angiogenesis of
retinoblastoma cells by targeting PDCD10 and GATA6. Oncol Rep.
33:2789–2796. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu M, An J, Huang M, Wang L, Tu B, Song
Y, Ma K, Wang Y, Wang S, Zhu H, et al: MicroRNA-492 overexpression
involves in cell proliferation, migration, and radiotherapy
response of cervical squamous cell carcinomas. Mol Carcinog.
57:32–43. 2018. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song X, Xie Y, Liu Y, Shao M and Yang W:
MicroRNA-492 overexpression exerts suppressive effects on the
progression of osteosarcoma by targeting PAK7. Int J Mol Med.
40:891–897. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu A, Wu K, Li M, Bao L, Shen X, Li S, Li
J and Yang Z: Upregulation of microRNA-492 induced by epigenetic
drug treatment inhibits the malignant phenotype of clear cell renal
cell carcinoma in vitro. Mol Med Rep. 12:1413–1420. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jiang J, Zhang Y, Yu C, Li Z, Pan Y and
Sun C: MicroRNA-492 expression promotes the progression of hepatic
cancer by targeting PTEN. Cancer Cell Int. 14:952014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shen F, Cai WS, Feng Z, Li JL, Chen JW,
Cao J and Xu B: MiR-492 contributes to cell proliferation and cell
cycle of human breast cancer cells by suppressing SOX7 expression.
Tumour Biol. 36:1913–1921. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
von Frowein J, Hauck SM, Kappler R, Pagel
P, Fleischmann KK, Magg T, Cairo S, Roscher A, von Schweinitz D and
Schmid I: MiR-492 regulates metastatic properties of hepatoblastoma
via CD44. Liver Int. 38:1280–1291. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
von Frowein J, Pagel P, Kappler R, von
Schweinitz D, Roscher A and Schmid I: MicroRNA-492 is processed
from the keratin 19 gene and up-regulated in metastatic
hepatoblastoma. Hepatology. 53:833–842. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pearce LR, Komander D and Alessi DR: The
nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol.
11:9–22. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jimenez-Velasco A, Roman-Gomez J, Agirre
X, Barrios M, Navarro G, Vazquez I, Prosper F, Torres A and
Heiniger A: Downregulation of the large tumor suppressor 2
(LATS2/KPM) gene is associated with poor prognosis in acute
lymphoblastic leukemia. Leukemia. 19:2347–2350. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Takahashi Y, Miyoshi Y, Morimoto K,
Taguchi T, Tamaki Y and Noguchi S: Low LATS2 mRNA level can predict
favorable response to epirubicin plus cyclophosphamide, but not to
docetaxel, in breast cancers. J Cancer Res Clin Oncol. 133:501–509.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Powzaniuk M, McElwee-Witmer S, Vogel RL,
Hayami T, Rutledge SJ, Chen F, Harada S, Schmidt A, Rodan GA,
Freedman LP and Bai C: The LATS2/KPM tumor suppressor is a negative
regulator of the androgen receptor. Mol Endocrinol. 18:2011–2023.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chakraborty S, Khare S, Dorairaj SK,
Prabhakaran VC, Prakash DR and Kumar A: Identification of genes
associated with tumorigenesis of retinoblastoma by microarray
analysis. Genomics. 90:344–353. 2007. View Article : Google Scholar : PubMed/NCBI
|
